Fas相关死亡结构域蛋白在乳腺癌中表达的临床病理研究
|
摘要
目的探讨Fas相关死亡结构域蛋白在乳腺癌中表达的临床病理特点。方法选择2013年2月~2017年2月我院收治的行乳腺肿瘤手术治疗患者的人体石蜡包埋组织标本148例,其中乳腺良性病变26例(A组),无淋巴结转移乳腺癌58例(B组),淋巴结转移乳腺癌64例(C组)。所有标本均实施免疫组化检查,分析Fas相关死亡结构域蛋白表达。结果 Fas相关死亡结构域蛋白表达于乳腺癌癌细胞胞浆内和乳腺良性病变上皮细胞内。B组中Fas相关死亡结构域蛋白表达较弱,染色范围较小,染色深度均较低;A组、C组中Fas相关死亡结构域蛋白表达较弱,染色深度强。A、B、C三组Fas相关死亡结构域蛋白阳性表达率分别为88.5%(23/26)、46.6%(27/58)、65.6%(42/64),A组高于B组、C组,差异有统计学意义(P<0.05)。在乳腺癌患者中,淋巴结转移、确诊年龄与Fas相关死亡结构域蛋白表达有关(P<0.05),但临床分期、组织学类型与Fas相关死亡结构域蛋白表达无关(P>0.05)。结论 Fas相关死亡结构域蛋白与乳腺癌淋巴结转移、确诊年龄有着密切的关系,但与临床分期、组织学类型无关,需引起高度关注。
Objective To explore the clinicopathological features of Fas-related death domain proteins expression in breast cancer.Methods From February 2013 to February 2017,148 cases of paraffin-embedded tissue specimens from patients undergone tumor surgeries were selected.There were benign breast lesions in 26 cases(group A),breast cancer without lymph node metastasis in 58 cases(group B),and breast cancer with lymph node metastasis in 64 cases(group C).All specimens were performed with immunohistochemical examinations in order to analyze the proteins expression of Fas-related death domain.Results It was detected that Fas-related death domain proteins were expressed in the intracytoplasm of breast cancer cells and epithelial cells of benign breast lesions.In group B,the expression of Fas-related death domain proteins was weak and dyeing range and depth were small compared with those in groups of A and C,which were in slight expression and deep dyeing.The positivity expression rates of Fas-related death domain proteins in groups of A,B,and C were 88.5%(23/26),46.6%(27/58),and 65.6%(42/64) respectively.The positivity expression rate in group A was higher than that in groups of B and C with statistical differences(P<0.05).For breast cancer patients,lymph node metastasis and age with a definite diagnosis were associated with Fas-related death domain protein expression(P<0.05).However,the clinical stage and histological type were not related to the expression of Fas-related death domain protein(P>0.05).Conclusion The expression of Fas-related death domain proteins is closely related to the lymph node metastasis and age with a definite diagnosis of breast cancer,but it has nothing to do with the clinical stage and histological type,to which should be paid high attention.
Objective To explore the clinicopathological features of Fas-related death domain proteins expression in breast cancer.Methods From February 2013 to February 2017,148 cases of paraffin-embedded tissue specimens from patients undergone tumor surgeries were selected.There were benign breast lesions in 26 cases(group A),breast cancer without lymph node metastasis in 58 cases(group B),and breast cancer with lymph node metastasis in 64 cases(group C).All specimens were performed with immunohistochemical examinations in order to analyze the proteins expression of Fas-related death domain.Results It was detected that Fas-related death domain proteins were expressed in the intracytoplasm of breast cancer cells and epithelial cells of benign breast lesions.In group B,the expression of Fas-related death domain proteins was weak and dyeing range and depth were small compared with those in groups of A and C,which were in slight expression and deep dyeing.The positivity expression rates of Fas-related death domain proteins in groups of A,B,and C were 88.5%(23/26),46.6%(27/58),and 65.6%(42/64) respectively.The positivity expression rate in group A was higher than that in groups of B and C with statistical differences(P<0.05).For breast cancer patients,lymph node metastasis and age with a definite diagnosis were associated with Fas-related death domain protein expression(P<0.05).However,the clinical stage and histological type were not related to the expression of Fas-related death domain protein(P>0.05).Conclusion The expression of Fas-related death domain proteins is closely related to the lymph node metastasis and age with a definite diagnosis of breast cancer,but it has nothing to do with the clinical stage and histological type,to which should be paid high attention.
引文
[1]邓亚平,钟晶敏,李晶,等.Fas相关死亡结构域蛋白在乳腺癌中表达的临床病理研究[J].现代生物医学进展,2016,16(26):5068-5071,5084.
[2]李小龙,成宏,赵晨晖,等.乳腺癌临床病理指标以及分子分型对TEC新辅助化疗病理完全缓解的预测价值[J].肿瘤防治研究,2013,40(6):599-603.
[3]钟芳芳,张巍,王成辉,等.上海汉族和新疆维吾尔族女性乳腺癌临床病理特征的比较[J].中国癌症杂志,2014,24(1):21-28.
[4]梁奋莉,曹伟,李林瑞,等.三阴性乳腺癌临床病理特点及预后因素分析[J].现代肿瘤医学,2013,21(2):294-298.
[5]王春妍,胡东胜,刘亚敏.大承气汤对急性肝衰竭大鼠FADD介导的肝细胞凋亡作用研究[J].中国实验方剂学杂志,2013,19(20):234-237.
[6]栗永生.Fas相关死亡结构域蛋白基因沉默对帕金森病模型鼠黑质凋亡相关蛋白的影响[D].青岛:青岛大学,2013:15.
[7]汤红平,谢闺娥,黄犁,等.106例青年女性乳腺癌临床病理特点的回顾性分析[J].中华乳腺病杂志(电子版),2013,7(3):28-31.
[8]秦颖,张同先,张巍,等.青年乳腺癌临床病理特点分子分型及预后分析[J].中国肿瘤临床,2014,41(4):231-236.
[9]杨文涛.个体化诊治时代的乳腺癌病理诊断[J].中国卫生产业,2013,22(7):556-560.
[10]李爱红,吴二兵,张元媛,等.Fas和FADD在6-OHDA诱导的帕金森病模型大鼠黑质纹状体系统的表达[J].江苏医药,2013,39(15):1751-1753.
[11]李斐,张岳.香丹注射液对脑缺血再灌注大鼠细胞凋亡与FADD m RNA表达的影响[J].中国老年学,2013,33(16):3899-3900.
[12]金丽.水飞蓟宾增强TRAIL对MDA-MB-231细胞的凋亡诱导活性研究[J].浙江实用医学,2016,21(5):317-319.
[13]汤福想,刘玉玲.Fas、c FLIP及TGF-β1在宫颈鳞癌组织中的表达及意义[J].中国现代医学杂志,2016,26(19):52-57.
[14]徐睿鑫,李绍旦,刘毅,等.补肾活血颗粒对帕金森病模型大鼠黑质和纹状体中Fas、FADD表达的影响[J].北京中医药,2015,34(5):405-408.
[15]郑中华,李蕴潜,郭敏,等.肿瘤坏死因子相关凋亡诱导配体对非小细胞肺癌细胞凋亡的诱导作用及其机制[J].吉林大学学报(医学版),2013,39(1):16-18.
[16]胡坤.死亡结构域相关蛋白的研究进展[J].徐州医学院学报,2015,35(5):343-346.
[17]张文刚,杨润军.牛Fas相关死亡功能域蛋白(FADD)研究进展[J].中国牛业科学,2013,39(4):40-46.
[18]王欢,卢陈嘉,马威,等.金雀异黄素诱导乳腺癌MDAMB-231细胞凋亡的研究[J].中华乳腺病杂志(电子版),2013,7(5):7-11.
[2]李小龙,成宏,赵晨晖,等.乳腺癌临床病理指标以及分子分型对TEC新辅助化疗病理完全缓解的预测价值[J].肿瘤防治研究,2013,40(6):599-603.
[3]钟芳芳,张巍,王成辉,等.上海汉族和新疆维吾尔族女性乳腺癌临床病理特征的比较[J].中国癌症杂志,2014,24(1):21-28.
[4]梁奋莉,曹伟,李林瑞,等.三阴性乳腺癌临床病理特点及预后因素分析[J].现代肿瘤医学,2013,21(2):294-298.
[5]王春妍,胡东胜,刘亚敏.大承气汤对急性肝衰竭大鼠FADD介导的肝细胞凋亡作用研究[J].中国实验方剂学杂志,2013,19(20):234-237.
[6]栗永生.Fas相关死亡结构域蛋白基因沉默对帕金森病模型鼠黑质凋亡相关蛋白的影响[D].青岛:青岛大学,2013:15.
[7]汤红平,谢闺娥,黄犁,等.106例青年女性乳腺癌临床病理特点的回顾性分析[J].中华乳腺病杂志(电子版),2013,7(3):28-31.
[8]秦颖,张同先,张巍,等.青年乳腺癌临床病理特点分子分型及预后分析[J].中国肿瘤临床,2014,41(4):231-236.
[9]杨文涛.个体化诊治时代的乳腺癌病理诊断[J].中国卫生产业,2013,22(7):556-560.
[10]李爱红,吴二兵,张元媛,等.Fas和FADD在6-OHDA诱导的帕金森病模型大鼠黑质纹状体系统的表达[J].江苏医药,2013,39(15):1751-1753.
[11]李斐,张岳.香丹注射液对脑缺血再灌注大鼠细胞凋亡与FADD m RNA表达的影响[J].中国老年学,2013,33(16):3899-3900.
[12]金丽.水飞蓟宾增强TRAIL对MDA-MB-231细胞的凋亡诱导活性研究[J].浙江实用医学,2016,21(5):317-319.
[13]汤福想,刘玉玲.Fas、c FLIP及TGF-β1在宫颈鳞癌组织中的表达及意义[J].中国现代医学杂志,2016,26(19):52-57.
[14]徐睿鑫,李绍旦,刘毅,等.补肾活血颗粒对帕金森病模型大鼠黑质和纹状体中Fas、FADD表达的影响[J].北京中医药,2015,34(5):405-408.
[15]郑中华,李蕴潜,郭敏,等.肿瘤坏死因子相关凋亡诱导配体对非小细胞肺癌细胞凋亡的诱导作用及其机制[J].吉林大学学报(医学版),2013,39(1):16-18.
[16]胡坤.死亡结构域相关蛋白的研究进展[J].徐州医学院学报,2015,35(5):343-346.
[17]张文刚,杨润军.牛Fas相关死亡功能域蛋白(FADD)研究进展[J].中国牛业科学,2013,39(4):40-46.
[18]王欢,卢陈嘉,马威,等.金雀异黄素诱导乳腺癌MDAMB-231细胞凋亡的研究[J].中华乳腺病杂志(电子版),2013,7(5):7-11.